An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints

Summary

This study is locally amended study from CSTI571K2301 to evaluate the efficacy and safety of high-dose Glivec in Korean patients group with chronic phase of CML. Molecular response at 60 months after Glivec administration will be described.

Timeline

Start

2010-08

Primary completion

2011-07

Completion

2011-07

Drugs

Indications